Recruiting
PHASE4
INTERVENTIONAL
NCT06042153
DIALYSIS-TIR Study
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly. Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.
Detailed Description
The researchers also have a Data Safety Monitoring Plan in place.
Interventions
Name:
Semaglutide
Type:
DRUG
Description:
Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
Name:
Placebo
Type:
DRUG
Description:
Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
Primary Outcomes
Measure:
Change in TIR (70-180 mg/dl)
TimeFrame:
Baseline, 52 weeks
Description:
Measured in percentage by Continuous glucose monitor (CGM)
Trial Information
NCT ID
NCT06042153
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
University of Texas Southwestern Medical Center
Last Updated
December 15, 2025